Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

G Park K, Lee JH, Soriano E, Choi M, Bao K, Katagiri W, et al. Rapid and Selective Targeting of Heterogeneous Pancreatic Neuroendocrine Tumors. iScience. 2020;23(4):101006.

Mustafa S, VandenBussche CJ, Ali SZ, Siddiqui MT, Wakely PE. Cytomorphologic findings of low-grade fibromyxoid sarcoma. J Am Soc Cytopathol. 2020;9(3):191-201.

Muldoon JL, Wysozan TR, Toubin Y, Relich RF, Davis TE, Zhang C, et al. An unusual presentation of cutaneous histoplasmosis as a recurrent solitary and spontaneously healing lesion in an immunocompetent patient. Access Microbiol. 2020;2(9):acmi000156.

Racine-Brzostek SE, Yang HS, Chadburn A, Orlander D, An A, Campion TR, et al. COVID-19 Viral and Serology Testing in New York City Health Care Workers. Am J Clin Pathol. 2020;154(5):592-595.

Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Talebi A, et al. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020;159:245-293.

Dillard A, DeSimone RA, Hsu Y-, Ma L, Vasovic L, Racine-Brzostek S, et al. Flat line in the blood bank: code H (hyperfibrinolysis)? Transfusion. 2020;60(9):1894-1896.

Yang GC, Fried KO, Scognamiglio T. Can cytology and the Thyroid Imaging, Reporting, and Data System (TI-RADS) identify noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) before surgery? J Am Soc Cytopathol. 2020;9(3):159-165.

Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020;11(1):1987.

Arnold A, Imada EL, M Zhang L, Edward DP, Marchionni L, Rodriguez FJ. Differential gene methylation and expression of HOX transcription factor family in orbitofacial neurofibroma. Acta Neuropathol Commun. 2020;8(1):62.

Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020;130(4):1653-1668.